{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:15:42Z","timestamp":1740179742323,"version":"3.37.3"},"reference-count":10,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: El s\u00edndrome de Stevens-Johnson es una reacci\u00f3n medicamentosa severa. Las sulfamidas se\u00a0han asociado con reacciones medicamentosas, complicaciones, secuelas, incluso la muerte.\nReporte de caso: Paciente femenina de 40 a\u00f1os, con antecedentes m\u00e9dicos de endometriosis y colitis ulcerativa\u00a0cr\u00f3nica inflamatoria de reciente diagn\u00f3stico. Fue atendida en el servicio de Alergolog\u00eda del Hospital San\u00a0Juan de Dios de la Caja Costarricense del Seguro Social, y luego de 20 d\u00edas de tratamiento con sulfasalazina\u00a0tuvo una reacci\u00f3n medicamentosa severa en la piel, compatible con s\u00edndrome de Stevens-Johnson. La prueba\u00a0de transformaci\u00f3n linfocitaria result\u00f3 positiva, con lo que se confirm\u00f3 la sulfasalazina como el agente causal.\nConclusiones: La prueba de transformaci\u00f3n linfocitaria es un m\u00e9todo \u00fatil que puede confirmar el agente causal\u00a0y prevenir complicaciones importantes a futuro.\nPalabras clave: S\u00edndrome de Stevens-Johnson; reacci\u00f3n medicamentosa grave; sulfonamidas; sulfasalazina;\u00a0prueba de transformaci\u00f3n linfocitaria.<\/jats:p>","DOI":"10.29262\/ram.v70i1.1047","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T07:10:10Z","timestamp":1685776210000},"page":"38-42","source":"Crossref","is-referenced-by-count":1,"title":["S\u00edndrome de Stevens-Johnson en una paciente con prueba positiva de transformaci\u00f3n linfocitaria"],"prefix":"10.29262","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-4049","authenticated-orcid":false,"given":"Mariela","family":"Carvajal-Elizondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-417X","authenticated-orcid":false,"given":"Olga Patricia","family":"Monge-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-5677","authenticated-orcid":false,"given":"Ricardo","family":"Chinchilla-Monge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-0199","authenticated-orcid":false,"given":"Steve","family":"Quiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"39426","unstructured":"Hern\u00e1ndez C.A, Restrepo R, Mej\u00eda M. S\u00edndrome de Stevens-Johnson y necr\u00f3lisis epid\u00e9rmica t\u00f3xica. Rev Asoc Colomb Dermatol. 2011;19: 67-75."},{"key":"39427","doi-asserted-by":"crossref","unstructured":"Harr T, French L.E. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet Journal of Rare Diseases. 2010; 5:39. http:\/\/www.ojrd.com\/content\/5\/1\/39","DOI":"10.1186\/1750-1172-5-39"},{"key":"39428","unstructured":"Sotelo-Cruz N. S\u00edndrome de Stevens-Johnson y necr\u00f3lisis epid\u00e9rmica t\u00f3xica en los ni\u00f1os. Gaceta M\u00e9dica de M\u00e9xico. 2012;148:265-275."},{"key":"39429","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-P\u00e9rez J, Caldevilla-Bernardo D, Perales-Pardo R, P\u00e9rez-G\u00f3mez F. S\u00edndrome de Stevens-Johnson: a prop\u00f3sito de un caso de fiebre y erupci\u00f3n cut\u00e1nea. Semergen. 2012; 38(4): 245-247.","DOI":"10.1016\/j.semerg.2011.09.002"},{"key":"39430","doi-asserted-by":"crossref","unstructured":"Frantz R, Huang S, Are A, Motaparthi K. Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicin. 2021; 57: 895. https:\/\/doi.org\/10.3390\/medicina57090895","DOI":"10.3390\/medicina57090895"},{"key":"39431","unstructured":"Mart\u00ednez-Cabriales S.A, G\u00f3mez-Flores M, Ocampo-Candiani J. Actualidades en farmacodermias severas: S\u00edndrome de Stevens-Johnson (SSJ) y Necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET). Gac Med Mex. 2015;151: 777-787."},{"key":"39432","doi-asserted-by":"crossref","unstructured":"Wetter D.A, Camilleri M.J. Clinical, Etiologic, and Histopathologic Features of Stevens-Johnson Syndrome During an 8-Year Period at Mayo Clinic. Mayo Clin Proc. 2010; 85(2): 131-138. \u2018","DOI":"10.4065\/mcp.2009.0379"},{"key":"39433","doi-asserted-by":"crossref","unstructured":"Barbarroja-Escudero J, S\u00e1nchez-Gonz\u00e1lez M.J, Antol\u00edn-Am\u00e9rigo D, y \u00c1lvarez de Mon Soto M. Indicaci\u00f3n e interpretaci\u00f3n de las pruebas in vitro de detecci\u00f3n etiol\u00f3gica al\u00e9rgica. Medicine. 2013; 11(29): 1825-1828.","DOI":"10.1016\/S0304-5412(13)70533-X"},{"key":"39434","doi-asserted-by":"crossref","unstructured":"Sachs B, Fatangare A, Sickmann A, Glassner A. Lymphocyte transformation test: History and current approaches. Journal of Immunological Methods. 2021. 493: 113036.","DOI":"10.1016\/j.jim.2021.113036"},{"key":"39435","doi-asserted-by":"crossref","unstructured":"Schneider J.A, Cohen P.R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv Ther. 2017; DOI 10.1007\/s12325-017-0530-y","DOI":"10.1007\/s12325-017-0530-y"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T07:10:20Z","timestamp":1685776220000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v70i1.1047","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}